Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

ERK1/2 Inhibition Overcomes Resistance to Venetoclax in AML By Altering Drp1-Dependent Mitochondrial Fission and Metabolism

Priyanka Sharma, Sujan Piya, Natalia Baran, Anna Zal, Christopher J. Hindley, Kim-Hien Dao, Martin Sims, Tomasz Zal, Vivian Ruvolo, Michael Andreeff, Gautam Borthakur

Blood (2022) 140 (Supplement 1): 8789–8790.

https://doi.org/10.1182/blood-2022-167171

Published: 2022

Journal Articles

ERK1/2 Inhibition Overcomes Resistance in Acute Myeloid Leukemia (AML) and Alters Mitochondrial Dynamics

Priyanka Sharma, Sujan Piya, Huaxian Ma, Natalia Baran, Malgorzata Anna Zal, Christopher J. Hindley, Kim-Hien Dao, Martin Sims, Tomasz Zal, Vivian Ruvolo, Michael Andreeff, Gautam Borthakur

Blood (2021) 138 (Supplement 1): 3338.

https://doi.org/10.1182/blood-2021-151579

Published: 2021

Journal Articles

Co-Targeting E-Selectin/CXCR4 with GMI-1359 Facilitates AML Stem Cell Mobilization and Protects BM Niches from Anti-Leukemia Therapy

Kyung Hee Chang, Tomasz Zal, Mahesh Basyal, Lauren Ostermann, Muharrem Muftuoglu, Po Yee Mak, Yannan Jia, Wenjing Tao, Malgorzata Anna Zal, William E. Fogler, John L. Magnani, Weiguo Zhang, Bing Z Carter, Michael Andreeff

Blood (2021) 138 (Supplement 1): 3348.

https://doi.org/10.1182/blood-2021-153661

Published: 2021

Journal Articles

High Efficacy of Liposomal Annamycin (L-ANN) in Combination with Cytarabine in Syngeneic p53-Null AML Mouse Model

Tomasz Zal, PhDMSc, Rafal Zielinski, PhD, Krzysztof Grela, MSc, Roberto Cardenas-Zuniga, Stanislaw Skora, PhD, Izabela Fokt, PhD, Malgorzata Anna Zal, MSc, Michael Andreeff, MD PhD, Lidia Gil, MDPhD, Robert Shephard, MD PhD, Waldemar Priebe, PhD

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-143344

Published: 2020

Journal Articles

Combined Blockage of E-Selectin and CXCR4 (GMI-1359) Enhances Anti-Leukemia Effect of FLT3 Inhibition (Sorafenib) and Protects Hematopoiesis in Pre-Clinical AML Models

Weiguo Zhang, MD PhD, Kyung Hee Chang, PhD, Mahesh Basyal, BS, Yannan Jia, Lauren B Ostermann, BS, William E. Fogler, PhD, John L. Magnani, PhD, M Anna Zal, BS., MS, Tomasz Zal, PhDMSc, Michael Andreeff, MD PhD

Blood (2020) 136 (Supplement 1): 17–18.

https://doi.org/10.1182/blood-2020-140984

Published: 2020

Journal Articles

Dual CXCR4 and E-Selectin Inhibition (GMI-1359) Rapidly Increases AML Cellular Motility Prior to Intravasation and Vascular Niche Depletion Observed By Intravital Bone Marrow Two-Photon Microscopy

Tomasz Zal, PhDMSc, Malgorzata Anna Zal, MSc, Mateusz Rytelewski, PhD, Kyung Hee Chang, PhD, Rodrigo Jacamo, PhD, William E. Fogler, PhD, John L. Magnani, PhD, Michael Andreeff, MD PhD

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-143420

Published: 2020

Journal Articles

Biodistribution and Efficacy of L-Annamycin in a Novel Imageable AML Mouse Model

Rafal Zielinski, PhD, Krzysztof Grela, PhD, Stanislaw Skora, PhD, Rodrigo Jacamo, PhD, Izabela Fokt, PhD, Matthew Sander, Magdalena Remiszewski, PhD, Edward Felix, PhD, Meenakshi Shanmugasundaram, Malgorzata Anna Zal, MSc, Michael Andreeff, MD PhD, Waldemar Priebe, PhD, Tomasz Zal, PhD

Blood (2019) 134 (Supplement_1): 5150.

https://doi.org/10.1182/blood-2019-131977

Published: 2019

Journal Articles

Intravital Imaging of Bright Cyan-Fluorescent AML Model Reveals Impact of CXCR4 Inhibitor on AML and Immune Cell Dynamics

Tomasz Zal, PhD, Mateusz Rytelewski, PhD, Rodrigo Jacamo, PhD, Malgorzata Anna Zal, MSc, Meenakshi Shanmugasundaram, Michael Andreeff, MD PhD

Blood (2019) 134 (Supplement_1): 2674.

https://doi.org/10.1182/blood-2019-131945

Published: 2019

Journal Articles

Anti-Leukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody-Conjugate in Acute Myeloid Leukemia

Lina Han, PhD, Eric Rowinsky, MD, Christopher Brooks, PhD, Tomasz Zal, M. Anna Zal, Jared K Burks, PhD, Jin Zhou, MD PhD, Stefan O. Ciurea, MD, Gheath Alatrash, Jorge E. Cortes, Hagop M. Kantarjian, MD, Michael Andreeff, MD PhD, Farhad Ravandi, MD, Marina Konopleva, MD PhD

Blood (2014) 124 (21): 981.

https://doi.org/10.1182/blood.V124.21.981.981

Published: 2014

Journal Articles

The Dynamics of Stroma-Leukemia Interaction in the Hypoxic BM Niches in Vivo

Karine G. Harutyunyan, PhD, Felix Nwajei, M. Anna Zal, David A Fruman, PhD, Saradhi Mallampati, PhD, Xiaoping Sun, MD PhD, Tomasz Zal, Marina Konopleva, MD PhD

Blood (2014) 124 (21): 2396.

https://doi.org/10.1182/blood.V124.21.2396.2396

Published: 2014

NARROW

ERK1/2 Inhibition Overcomes Resistance to Venetoclax in AML By Altering Drp1-Dependent Mitochondrial Fission and Metabolism

ERK1/2 Inhibition Overcomes Resistance in Acute Myeloid Leukemia (AML) and Alters Mitochondrial Dynamics

Co-Targeting E-Selectin/CXCR4 with GMI-1359 Facilitates AML Stem Cell Mobilization and Protects BM Niches from Anti-Leukemia Therapy

High Efficacy of Liposomal Annamycin (L-ANN) in Combination with Cytarabine in Syngeneic p53-Null AML Mouse Model

Combined Blockage of E-Selectin and CXCR4 (GMI-1359) Enhances Anti-Leukemia Effect of FLT3 Inhibition (Sorafenib) and Protects Hematopoiesis in Pre-Clinical AML Models

Dual CXCR4 and E-Selectin Inhibition (GMI-1359) Rapidly Increases AML Cellular Motility Prior to Intravasation and Vascular Niche Depletion Observed By Intravital Bone Marrow Two-Photon Microscopy

Biodistribution and Efficacy of L-Annamycin in a Novel Imageable AML Mouse Model

Intravital Imaging of Bright Cyan-Fluorescent AML Model Reveals Impact of CXCR4 Inhibitor on AML and Immune Cell Dynamics

Anti-Leukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody-Conjugate in Acute Myeloid Leukemia

The Dynamics of Stroma-Leukemia Interaction in the Hypoxic BM Niches in Vivo

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only